Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis  

作　　者：Fangfang Li Fanping Meng Quanxin Jin Changyuan Sun Yingxin Li Honghua Li Songzhu Jin 

机构地区：[1]Department of Immunology and Pathogenic Biology,College of Medicine,Yanbian University

出　　处：《Neural Regeneration Research》2014年第8期851-856,共6页中国神经再生研究（英文版）

基　　金：supported by the National Natural Science Foundation of China,No.30360100,30760234,30860260,81160373,81360458

摘　　要：Single-chain variable domain fragment （scFv） 637 is an antigen-specific scFv of myasthenia gravis. In this study, scFv and human serum albumin genes were conjugated and the fusion pro-tein was expressed in Pichia pastoris. The afifnity of scFv-human serum albumin fusion protein to bind to acetylcholine receptor at the neuromuscular junction of human intercostal muscles was detected by immunolfuorescence staining. The ability of the fusion protein to block myas-thenia gravis patient sera binding to acetylcholine receptors and its stability in healthy serum were measured by competitive ELISA. The results showed that the inhibition rate was 2.0-77.4%, and the stability of fusion protein in static healthy sera was about 3 days. This approach suggests the scFv-human serum albumin is a potential candidate for speciifc immunosuppressive therapy of myasthenia gravis.Single-chain variable domain fragment （scFv） 637 is an antigen-specific scFv of myasthenia gravis. In this study, scFv and human serum albumin genes were conjugated and the fusion pro-tein was expressed in Pichia pastoris. The afifnity of scFv-human serum albumin fusion protein to bind to acetylcholine receptor at the neuromuscular junction of human intercostal muscles was detected by immunolfuorescence staining. The ability of the fusion protein to block myas-thenia gravis patient sera binding to acetylcholine receptors and its stability in healthy serum were measured by competitive ELISA. The results showed that the inhibition rate was 2.0-77.4%, and the stability of fusion protein in static healthy sera was about 3 days. This approach suggests the scFv-human serum albumin is a potential candidate for speciifc immunosuppressive therapy of myasthenia gravis.

关 键 词：nerve regeneration myasthenia gravis acetylcholine receptor anti-acetylcholine re-ceptor antibody single-chain variable domain fragment human serum albumin fusion protein immunosuppressive therapy autoimmune disease NSFC grant neural regeneration 

分 类 号：R746.1[医药卫生—神经病学与精神病学]